Industry News (Combivir)

Compact Formulation for HIV Treatment Available in Canada

Published in AIDS Weekly, December 21st, 1998

Glaxo Wellcome Inc., Laval, Quebec, Canada, and BioChem Pharma, Inc., announced that the Health Protection Branch of Health Canada has approved Combivir for treatment of HIV patients.

Combivir is a safe and effective, HIV compact formulation and could improve treatment adherence for HIV/AIDS patients requiring potent nucleoside analogue therapy, the companies say. Combivir is a fixed dose formulation combining two anti-HIV drugs, 3TC (lamivudine) and Retrovir (AZT/zidovudine), into one tablet. Taken twice daily, Combivir offers the advantage of reducing the number of tablets by up to six tablets per day or 2,190 tablets per year compared to the use of the two other...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1998-12-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry